The granting of a new European patent for CM-101 significantly strengthens Chemomab's intellectual property, potentially increasing its market exclusivity and competitive edge in treating rare fibro-inflammatory diseases. This development is likely to be viewed positively by investors, as it not only validates the company's research and development efforts but also enhances its potential for future revenue generation. The completion of patient enrollment for the Phase 2 SPRING trial and the anticipation of results by mid-2024 further underscore the progress in CM-101's clinical development, potentially driving investor interest and stock price in the short term.